| |
| |
|
| Insider
Information: |
Espinoza Octavio |
| Relationship: |
Chief Financial Officer |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
29,755 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,125,102 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
29,755 |
|
|
| Total
Value |
$2,125,102 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
Chief Financial Officer |
2024-02-28 |
29,755 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
14 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
Chief Financial Officer |
• – – |
2024-02-28 |
4 |
S |
$88.46 |
$12,384 |
D/D |
(140) |
29,755 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Financial Officer |
• – – |
2024-02-28 |
4 |
OE |
$55.75 |
$71,564 |
D/D |
1,264 |
29,895 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Financial Officer |
• – – |
2024-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
7,208 |
28,631 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Financial Officer |
• – – |
2024-02-15 |
4 |
D |
$74.65 |
$110,407 |
D/D |
(1,479) |
21,423 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Financial Officer |
• – – |
2023-12-05 |
4 |
D |
$59.61 |
$75,645 |
D/D |
(1,269) |
22,902 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Financial Officer |
• – – |
2023-10-01 |
4 |
D |
$59.92 |
$20,732 |
D/D |
(346) |
24,171 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Financial Officer |
• – – |
2023-06-30 |
4 |
A |
$56.78 |
$21,293 |
D/D |
375 |
24,517 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Financial Officer |
• – – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,046 |
24,142 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Financial Officer |
• – – |
2023-02-15 |
4 |
D |
$72.98 |
$61,960 |
D/D |
(849) |
18,096 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Financial Officer |
• – – |
2022-12-30 |
4 |
A |
$56.78 |
$15,615 |
D/D |
275 |
18,945 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Financial Officer |
• – – |
2022-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
18,670 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Financial Officer |
• – – |
2022-11-30 |
4 |
D |
$72.90 |
$86,532 |
D/D |
(1,187) |
7,670 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Financial Officer |
• – – |
2022-11-09 |
4 |
S |
$75.64 |
$128,283 |
D/D |
(1,696) |
8,857 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Financial OfficerOfficer |
• – – |
2022-11-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,553 |
|
% |
|
14 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
